REVVITY, INC.
Ownership & governance
Executives 5Directors 10Avg age 61Avg tenure 6.1y
PS
Prahlad Singh
Chief Executive Officer
Age 61Since 2019-12-29Profile →
+14
Executives5
Board of directors10
AM
Alexis Michas→
Chairman
Age 68Since 2019-12-29
PB
Peter Barrett→
Director/Board Member
Age 74Since 2012-02-06
FW
Frank R. Witney Witney→
Director/Board Member
Age 72Since 2016-07-26
SC
Samuel Chapin→
Director/Board Member
Age 68Since 2016-10-14
PS
Prahlad Singh→
Director/Board Member
Age 61Since 2019-08-20
PW
Pascale Witz→
Director/Board Member
Age 59Since 2017-10-29
MV
Michel Vounatsos→
Director/Board Member
Age 64Since 2020-02-29
MM
Michelle McMurry-Heath→
Director/Board Member
Age 56Since 2022-07-21
Shareholders4
| Name | Stake | Shares |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19.9 % | 22,198,422 |
| T. Rowe Price International Ltd. | 9.045 % | 10,090,158 |
| Edgepoint Investment Group, Inc. | 7.889 % | 8,800,863 |
| Janus Henderson Investors US LLC | 7.483 % | 8,348,127 |
Catalog · 2026-07-09
Registry officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Alexis Michas | Chairman | 2019-12-29 | - |
| Bryan Kipp | Chief Tech/Sci/R&D Officer | 2024-04-30 | - |
| Madhuri Hegde | Chief Tech/Sci/R&D Officer | 2023-04-30 | - |
| Maxwell Krakowiak | Director of Finance/CFO | 2022-09-05 | - |
| Prahlad Singh | Chief Executive Officer | 2019-12-29 | - |
| Yi Ping Lin | Chief Tech/Sci/R&D Officer | 2022-12-31 | - |
| Frank R. Witney Witney | Director/Board Member | 2016-07-26 | - |
| Michael Klobuchar | Director/Board Member | 2024-01-31 | - |
Registry · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| EUROIMMUN Medizinische Labordiagnostika AG | Medical Specialties |
| EUROIMMUN Medizinische Labordiagnostika AG | Medical Specialties |
| Biosense Technologies Pvt Ltd. | Electronic Equipment/Instruments |
| Biosense Technologies Pvt Ltd. | Electronic Equipment/Instruments |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 141.53Range 110–165Analysts 15
110Mean 141.53165
- Buy 6
- Hold 11
- Strong sell 1
Broker actions40 of 83
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Equal-Weight | 160 | 2026-10-07 |
| William Blair | Initiated | Outperform | — | 2026-10-06 |
| Keybanc | Maintained | Overweight | 165 | 2026-09-04 |
| RBC Capital | Initiated | Sector Perform | 135 | 2026-09-01 |
| Evercore ISI Group | Maintained | Outperform | 126 | 2026-08-05 |
| Evercore ISI Group | Maintained | Outperform | 125 | 2026-07-06 |
| Barclays | Maintained | Equal-Weight | 105 | 2026-05-07 |
| JP Morgan | Maintained | Neutral | 90 | 2026-05-06 |
| TD Cowen | Maintained | Buy | 120 | 2026-05-06 |
| Stifel | Maintained | Hold | 100 | 2026-05-06 |
| Baird | Maintained | Outperform | 125 | 2026-05-04 |
| Goldman Sachs | Maintained | Neutral | 95 | 2026-04-14 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.